– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO ...
Upstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of ...
Indonesia this year plans to offer 10 exploration blocks (working areas or WKs) with the initial tender potentially being launched as early as next month. “We plan maybe in early March, we want to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results